Skip to content

Clinical trials

Phase 2 Drug-Related Side Effects and Adverse Reactions trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Drug-Related Side Effects and Adverse Reactions Phase: Phase 2 Country / region: United States Clear all

20 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20012
20021
20031
20042
20051
20201
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Terminated2
Active, not recruiting1
Recruiting1
Unknown status1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Agency for Healthcare Research and Quality (AHRQ)1
Alliance for Clinical Trials in Oncology1
Children's Oncology Group1
Eli Lilly and Company1
Herbert Irving Comprehensive Cancer Center1
Jonsson Comprehensive Cancer Center1
Ligand Pharmaceuticals1
Massachusetts General Hospital1
National Center for Complementary and Integrative Health (NCCIH)1
OHSU Knight Cancer Institute1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Drug-Related Side Effects and Adverse Reactions20
Lung Neoplasms6
Carcinoma, Non-Small-Cell Lung4
Lymphoma4
Radiation Injuries4
Breast Neoplasms3
Leukemia3
Precursor Cell Lymphoblastic Leukemia-Lymphoma3
Adenocarcinoma of Lung2
Blast Crisis2

Trials

Showing 1 to 20 of 20. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.